The FDA release from the pulmonary malignancy study is a clear positive catalyst, removing a long-standing regulatory overhang. The upcoming PDUFA date (May 29, 2026) for the pediatric sBLA adds near-term binary catalyst risk. Traders should watch for the pediatric decision as the next major event.
Price Chart
Executive Summary
MannKind announced the FDA released it from a postmarketing requirement for Afrezza—a five-year pulmonary malignancy study in 8,000-10,000 type 2 diabetes patients—eliminating a major regulatory overhang. The only remaining postmarketing requirement is a pediatric efficacy/safety assessment, with a PDUFA target action date of May 29, 2026. Separately, the company provided a clinical update on the INHALE-1st pediatric study, with data expected in late 2027.
Key Facts
- FDA released MannKind from a postmarketing requirement to assess pulmonary malignancy risk in 8,000-10,000 Afrezza patients
- Only remaining postmarketing requirement is pediatric efficacy/safety assessment (sBLA accepted October 2025, PDUFA date May 29, 2026)
- INHALE-1st study: 8 additional sites activated, up to 100 participants expected, data expected late 2027
Financial Impact
Elimination of a costly, multi-year postmarketing study removes a significant future expense and regulatory risk; no dollar amount disclosed
Risk Factors
- PDUFA decision on pediatric sBLA (May 29, 2026) could result in a Complete Response Letter
- INHALE-1st data not expected until late 2027, limiting near-term pipeline catalysts
- No financial figures disclosed; cost savings from released postmarketing requirement are unquantified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-243074 |
| Document: 0001193125-26-243074-index-headers.html | 0001193125-26-243074 |
| Document: 0001193125-26-243074-index.html | 0001193125-26-243074 |
| Document: 0001193125-26-243074.txt | 0001193125-26-243074 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | Press Release | $3.85 $4.09 | ▲ +6.23% | ▲ +1.21% | $3.80 (−1.30%) |
Jul 24, 2026 10w ago | 8-K | $3.95 $4.07 | ▲ +3.04% | ▼ −0.26% | $3.80 (−3.80%) |
Jul 18, 2026 10w ago | Insider Cluster | $3.98 $3.90 | ▼ −2.01% | ▼ −6.13% | $3.80 (−4.52%) |
Jun 3, 2026 17w ago | Press Release | $3.36 $4.52 | ▲ +34.52% | ▲ +35.52% | $3.80 (+13.10%) |
Jun 2, 2026 17w ago | 8-K | $3.43 $4.05 | ▲ +18.08% | ▲ +19.64% | $3.80 (+10.79%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.80 (+0.80%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.80 (+0.80%) |
May 28, 2026 18w ago | 8-K | $3.64 $4.14 | ▲ +13.74% | ▲ +16.88% | $3.80 (+4.40%) |
May 27, 2026 18w ago | Press Release | $3.55 $3.93 | ▲ +10.70% | ▲ +12.61% | $3.80 (+7.04%) |
May 12, 2026 20w ago | Insider Cluster | $3.28 $3.63 | ▲ +10.67% | ▲ +12.40% | $3.80 (+15.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access